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Introduction: Previous work from this laboratory demonstrated that magnetic resonance imaging (MRI) detects
early murine mammary cancers and reliably differentiates between in situ and invasive cancer. Based on this
previous work, we used MRI to study initiation and progression of murine mammary cancer, and monitor the
transition from the in situ to the invasive phase.
Methods: In total, seven female C3(1) SV40 Tag mice were imaged every two weeks between the ages of 8 to 23
weeks. Lesions were identified on T2-weighted images acquired at 9.4 Tesla based on their morphology and growth
rates. Lesions were traced manually on MR images of each slice. Volume of each lesion was calculated by adding
measurements from individual slices. Plots of lesion volume versus time were analyzed to obtain the specific growth
rate (SGR). The time at which in situ cancers (referred to as ‘mammary intraepithelial neoplasia (MIN)’) and invasive
cancers were first detected; and the time at which in situ cancers became invasive were recorded.
Results: A total of 121 cancers (14 to 25 per mouse) were identified in seven mice. On average the MIN lesions
and invasive cancers were first detected when mice were 13 and 18 weeks old, respectively. The average SGR was
0.47 ± 0.18 week-1 and there were no differences (P >0.05) between mice. 74 lesions had significantly different
tumor growth rates before and after ~17 weeks of age; with average doubling times (DT) of 1.88 and 1.27 weeks,
respectively. The average DT was significantly shorter (P <0.0001) after 17 weeks of age. However, the DT for some
cancers was longer after 17 weeks of age, and about 10% of the cancers detected did not progress to the invasive
stage.
Conclusions: A wide range of growth rates were observed in SV40 mammary cancers. Most cancers transitioned to
a more aggressive phenotype at approximately 17 weeks of age, but some cancers became less aggressive. The
results suggest that the biology of mammary cancers is extremely heterogeneous. This work is a first step towards
use of MRI to improve understanding of factors that control and/or signal the development of aggressive breast
cancer.Introduction
The processes that characterize and trigger progression of
pre-invasive ductal carcinoma in situ to invasive ductal
carcinoma breast cancer are not well understood [1]. This
process cannot ethically be studied in patients. There is
therefore a critical need for non-invasive studies of breast
cancer progression in animal models. Here we report
on serial magnetic resonance imaging (MRI) studies of* Correspondence: gskarczm@uchicago.edu
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unless otherwise stated.growth patterns of in situ and invasive mammary cancer
in a murine model of breast cancer.
Transgenic mouse models of human breast cancer pro-
vide an excellent experimental framework for studying the
natural history of in situ and invasive cancer [2-5]. The fe-
male C3(1) SV40 Tag transgenic mouse is a widely used
model for breast cancer research [6-9]. SV40 Tag mice de-
velop mammary cancer that resembles human ductal
breast carcinoma, including progression through atypical
ductal hyperplasia (∼8 weeks of age), in situ cancers (re-
ferred to as mammary intraepithelial neoplasia (MIN) in
mice) (∼12 weeks of age) and invasive ductal carcinoma
(∼16 weeks of age) [10,11]. MIN is similar to humanis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fan et al. Breast Cancer Research  (2014) 16:495 Page 2 of 10ductal carcinoma in situ and is considered a precursor to
invasive cancer [12]. Due to the small size of in situ mam-
mary neoplasias in mouse models, high-resolution im-
aging techniques are required to study how lesions
develop, grow and progress over time.
Previous work in this laboratory demonstrated that
non-invasive T2-weighted MRI can reliably detect small
in situ cancers and distinguish between in situ and inva-
sive cancers [2]. Jansen and colleagues in this laboratory
studied SV40 Tag mouse mammary cancer progression
from 10 to 21 weeks of age using MRI [3]. Their re-
search produced image-based evidence that some in situ
mammary cancers do not progress to invasive cancers.
However, these previous imaging studies were limited to
only one side of mouse inguinal glands and images were
acquired using spoiled gradient echo imaging at 2-week
or 3-week intervals between 10 and 21 weeks of age.
Generally, more cancers develop in the upper mouse
mammary gland than in the lower mammary gland [5].
Therefore, whole mouse imaging that allows evaluation
of all of the mammary glands is necessary in order
to gain a better understanding of mammary cancer
progression.
In this research, we used whole-body MRI screening
for lesion assessment in all SV40 mice mammary glands
from ~8 to ~23 weeks of age, at 2-week intervals. Mam-
mary cancers were identified and characterized on high-
resolution T2-weighted images to follow the transition
from in situ to invasive cancer. The volumes of lesions




Female C3(1) SV40 Tag transgenic mice (n = 7) were stud-
ied. All procedures were carried out with approval from the
University of Chicago’s Animal Care and Use Committee.
Mice were imaged approximately every 2 weeks beginning
at age ~8 weeks and ending at ~23 weeks. Animals were
anesthetized prior to imaging experiments, and anesthesia
was maintained during imaging as 1.5% isoflurane.
Temperature, heart rate and respiration rate were moni-
tored with an optical detection system from SA Instru-
ments (Stony Brook, NY, USA), designed for use in small
animal MRI. The temperature was kept within normal
range using a temperature-controlled fiber optic probe and
heating system. The respiration rate was maintained at ~55
breaths/minute and used to obtain gated images.
Imaging protocols
MRI experiments were performed on a 9.4 Tesla Bruker
(Billerica, MA, USA) small animal scanner with 11.6 cm
inner diameter and actively shielded gradient coils (max-
imum constant gradient strength for all axes: 230 mT/m).After being fitted with physiological monitoring equip-
ment, mice were taped into a plastic semicircular holder
and placed inside a quadrature coil (outside diameter/in-
side diameter = 59/35 mm, length = 38 mm; Bruker).
Axial low-resolution gradient echo images (repetition
time/echo time = 600/3.2 milliseconds, field of view =
25.6 mm, array size = 1282, slice thickness = 1.0 mm,
number of slices = 41, flip angle = 30°, number of excita-
tions = 2) with fat suppression and respiratory gating were
acquired first to ensure that the area of interest was at the
center of the magnet and detector. Axial high-resolution
multislice rapid acquisition with relaxation enhancement
spin echo T2-weighted images (repetition time/echo time
effective = 4,000/20.3 milliseconds, field of view = 25.6 mm,
matrix size = 2562, slice thickness = 0.5 mm, slice gap = 1
mm, number of slices = 41, number of excitations = 2,
rapid acquisition with relaxation enhancement factor = 4)
with fat suppression and respiratory gating were then ac-
quired. First a complete set of images were acquired for
the upper (thoracic, cervical, axillary) glands, and then a
complete set of images were acquired for the lower (in-
guinal) mammary glands. For both the upper and lower
glands, two interleaved sets of images were acquired to
cover the slice gaps and then combined together for a
total of 82 slices. Thus, a total of 164 T2-weighted slices
were acquired for each mouse (82 from the upper glands,
and 82 from the lower glands).
Image analysis
Data analysis was performed using programs written in
IDL (Exelis VIS, Inc., Boulder, CO, USA). A researcher
(XF) with more than 15 years of animal MRI experience
and a veterinary technician (EM) with 8 years of small
animal imaging experience analyzed all of the images to
identify the tumors. Previous studies of this model cor-
related features identified on MRI with histology and
established that small scattered foci with largest diam-
eter between 100 and 400 μm, intensity 1.5 times that of
muscle or greater on T2-weighted images, and with
elongated morphology (resembling individual ducts) are
almost always in situ cancers [3]. Solid lesions larger
than 500 μm in largest diameter are always invasive can-
cer. Lymph nodes were identified based on their loca-
tion, oval shape and signal intensity close to that of
muscle. In addition, lymph ducts were identified based
on their chain-like morphology and their direct connec-
tion to lymph nodes. This morphology clearly distin-
guished lymph ducts from in situ cancers.
For each cancer identified, we recorded the age (of the
mouse) at which MIN lesions were first detected (T0
(MIN), weeks) and the age at which they were last de-
tected (T1(MIN), weeks), generally due to the transition to
the invasive phenotype, and the age at which invasive can-
cers (T0(IC), weeks) were first detected. The total time
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was then calculated as follows:
DMIN ¼ T1 MINð Þ−T0 MINð Þ þ 1: ð1Þ
Thus, if a MIN lesion was detected only once (that is,
T1(MIN) = T0(MIN)), then DMIN is equal to 1 week.
The area of each tumor was manually traced on each slice
in which the tumor appeared on T2-weighted magnetic res-
onance images, and multiplied by the slice thickness to de-
termine the volume of the tumor in each slice. All of the
slice volumes for each tumor were then added together to
estimate the final tumor volume [13]. The tumor SGR (ρ)
was calculated by fitting the tumor volumes as a function of
time (V(t)) to the following equation [14]:
V fit tð Þ ¼ V 0 exp ρ t−t0ð Þð Þ; ð2Þ
where t (weeks) is the age of the mouse and V0 is
tumor volume detected at initial time t0 (weeks). To
evaluate the goodness of fit, an average value was calcu-
lated for each curve:
r ¼ V tð Þ−V fit tð Þ
 = V tð Þ þ V fit tð Þ
 
If rave <0.05, the fit was considered excellent.
In many cases the growth curves could not be well ap-
proximated (rave > 0.05) by the simple mono-exponential
model (Equation 2), and two different stages of growth
were apparent. In those cases, we identified a transition
time (TT) at which the growth rate changed, and deter-
mined the doubling time (DT) before and after the TT.
The DT, rather than the SGR, was used for this compari-
son because of the small number of time points available
before and after the TT. The comparison of the DT as-
sumes that tumor volumes satisfy Equation 2 before and
after the TT with two different growth rates. To estimate
the TT, we defined:
r tð Þ ¼ V tð Þ−V fit tð Þ
 
= V tð Þ þ V fit tð Þ
 
; ð3Þ
for each cancer. If the value of Vfit(t) is close to the ex-
perimentally measured volume V(t), then r is very close
to 0. If Vfit(t) is significantly less than or greater than the
measured volume, then r approaches –1 or 1. We ap-
plied two-means clustering to r(t) to identify two clus-
ters around values of r close to zero and values of r
different from zero; these are designated clusters ‘0’ or
‘1’. For each cluster, composed of r(t) values measured at
different ages, the maximum age in each cluster was de-
termined. The TT was determined as the minimum of
these two maximum ages. This approximately corre-
sponds to the age that separates the two clusters. This
method was only applied to cancers that were sampled
at a minimum of four time points, and for which the de-
termined TT was not the first or last time point.For tumors with two different growth rates, the DT
before and after the TT was calculated from the follow-
ing formula [14]:
DT ¼ t2−t1ð Þ ln2= ln V 2=V 1ð Þ; ð4Þ
where t1 and t2 are two different ages, and V1 and V2
are the tumor volumes at these two ages. For time
points before the TT, t2 is the age at the TT and t1 is the
age at the scan immediately before the TT. The DT is
therefore the growth rate immediately before the week
at which the transition occurs. Similarly, for time points
after the TT, t1 is the age at the TT and t2 is the scan im-
mediately after the week at which the transition occurs.
The DT therefore gives the growth rate immediately
after the TT.
Statistical analysis
One-way analysis of variance and Tukey's honestly signifi-
cant difference test were performed to examine whether
SGRs were significantly different between seven mice.
Paired t tests were used to determine whether the DTs be-
fore and after the TT were different for pooled data from
all seven mice. P <0.05 was considered significant.
Results
High-resolution whole body magnetic resonance images
successfully detected early in situ cancer in all mammary
glands. Figure 1a shows a cancer in the thoracic mam-
mary gland from week ~10 to ~22. The cancer is less
than 150 μm at largest diameter and its intensity relative
to muscle is 1.5:1 at week 10; therefore it is classified as
in situ cancer. By week 14 the largest diameter of the
cancer is 1 mm and it is classified as invasive. After week
14, the size of the cancer increased dramatically. The
plot of the volume of this cancer as a function of mouse
age is shown in Figure 1b. Equation 2 (red line) does not
fit all of the experimental data (dots) accurately, espe-
cially at earlier times. It is clear from visual inspection of
the plot that there are two different tumor growth rates
before and after week ~15.
Figure 2a shows another cancer in an inguinal gland
from week ~11 to week ~23. The cancer is 200 μm at lar-
gest diameter with contrast relative to muscle of 1.6:1 at
week ~11, and therefore is classified as in situ cancer. It
develops into an invasive cancer at week ~15, and con-
tinues to grow after that. The plot of the volume of this
cancer as a function of mouse age is shown in Figure 2b.
Equation 2 (red line) fits the data (dots) closely.
The total number of individual lesions found in each
mouse ranged from 14 to 25. The numbers of in situ and
invasive cancers identified in each mouse at each age are
shown in Figure 3 (a to g correspond with mouse A to
mouse G) in a stacked column plot. For each mouse,
Figure 1 An identified cancer and corresponding plot of measured tumor volume as a function of mouse age. (a) A cancer (circled) in
the thoracic gland from week ~10 to ~22. A tiny cancer found at week 10 developed into an invasive cancer at week 14, and the size of cancer
increased dramatically after that. The displayed image field of view is 25 mm × 20 mm. (b) Plot of the tumor volume (black dots) calculated as a
function of mouse age and fitted (red line) with the simple exponential tumor growth model.
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was found, the average age at which each MIN lesion was
last detected, the time over which each MIN lesion was
detected, and the average age at which each invasive can-
cer was detected. On average, MIN was first detected at
13.0 weeks, last detected at 16.1 weeks, and the average
period over which MIN lesions were detected was 4.1
weeks. Invasive cancer was first detected at an average of
17.6 weeks of age.
A small percentage of cancers (10%) did not progress
from the in situ to the invasive stage during the observa-
tion period – on average from ~14 to ~21 weeks. The
average (± standard deviation) T0(MIN), T1(MIN) and D
(MIN) for in situ cancers that did not progress to the in-
vasive stage was 14.3 ± 2.4 weeks, 20.3 ± 2.0 weeks and
7.0 ± 2.4 weeks, respectively.
Figure 4 shows the box plot of SGR calculated by fit-
ting the growth of all lesions in seven different mice to a
mono-exponential function. The average SGR was 0.47
± 0.18/week and analysis of variance showed that there
are no significant differences in SGR among the mice.Figure 5 illustrates calculation of the TT for a tumor
growth curve that was not accurately fitted by the
mono-exponential model. Figure 5a shows the tumor
volume and fitted curve as a function of mouse age.
Figure 5b shows the corresponding r(t) values at each
time point. Two-means cluster analysis produced cluster
‘0’ containing the four points from 10 to 15 weeks and
cluster ‘1’ containing three points from 18 to 22 weeks.
Fifteen weeks was identified as the TT for this tumor;
that is, the time at which the tumor growth rate changed
significantly. In this example, the DT was 0.47 weeks
and 0.83 weeks before and after the TT, respectively.
Out of 121 cancers identified, the growth curves of 74
cancers were not well approximated by the mono-
exponential model and were analyzed as summarized
above to obtain two clusters of time points with differ-
ent DTs. The average TT for these cancers was ~16.6
weeks. This is close to the average time at which inva-
sive cancers were first detected (~17.6 weeks). Figure 6
shows a plot of the DT for 74 cancers before and after
the TT. For most cancers (51 of the 74, 69%), the DT
Figure 2 An identified cancer and corresponding plot of measured tumor volume as a function of mouse age. (a) A cancer (circled) in
the inguinal gland from week ~11 to ~23. Again, a tiny cancer found at week 10 developed into an invasive cancer at week 12, and then the size
of tumor increased exponentially after that. The displayed image field of view is 25 mm × 20 mm. (b) Plot of the tumor volume (black dots)
calculated as a function of mouse age and fitted (red line) with the simple exponential tumor growth model.
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P <0.000001 by paired t test) However, for 31% of can-
cers the DT was at least 27% longer after the TT; that is,
the growth rate of these cancers slowed significantly
(an average of 1.3 before TT vs. 1.6 weeks after TT,
P <0.0001). There was no significant difference in initial
volume or volume at 18 weeks between cancers that
grew more slowly after the TT and cancers that grew
more rapidly after the TT. Nine of the cancers that grew
more slowly after the TT and 12 of the cancers that grew
more rapidly after the TT were still in situ at 18 weeks
of age.
Finally, for the 74 lesions shown in Figure 6, we plot-
ted the tumor volume measured at 18 weeks as function
of the ratio of the DT before the TT to the DT after the
TT (Figure 7). Eighteen weeks of age was chosen be-
cause all seven mice were studied at this age. The plot
shows that cancers which were larger at 18 weeks tended
to exhibit a smaller increase, or a decrease in the DT
after TT relative to smaller cancers. The plot emphasizes
that while the DT decreased for many cancers after theTT, growth of a significant number of cancers slowed
after the TT.
Discussion
The average ages at which MIN lesions and invasive
cancers were first detected, 13 and 18 weeks respect-
ively, were close to those estimated by previous studies
of hematoxylin and eosin-stained tissue slices from mice
sacrificed at various ages [11]. The majority of MIN le-
sions identified by MRI progressed to invasive cancers
by the age of ~17 weeks. The simple exponential tumor
growth model provided poor fits to the data from 74 out
of a total of 121 cancers. In these 74 cases there were
two different phases of growth with a transition at ap-
proximately ~16 weeks of age. This was similar to the
average age at which MIN lesions in this group pro-
gressed to invasive lesions. For most of the 74 cancers,
the DT was significantly shorter after the TT. However,
for 31% of cancers, growth slowed significantly after the
TT. The cancers that grew more slowly after the TT
could not be distinguished from the cancers that grew
Figure 3 Number of lesions identified in each scan of each mouse. (a) to (g) Stacked bar-plots corresponding with mouse A to mouse G.
Total number of lesions found for each mouse ranged from 14 to 25, and more invasive cancers formed after mice were about 18 weeks old.
MIN, mammary intraepithelial neoplasia.
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the time the cancers were first detected, the volume at
18 weeks, or the duration of the in situ phase of these
cancers.Growth rates immediately before and after the TT
were compared based on the DT rather than the SGR.
In principle, the SGR provides a more accurate estimate
of tumor growth [15]. However, the goal here was to
Table 1 Age of mice at the time MIN is first detected,
average age when MIN is last detected, and average age









A 13.5 ± 2.1 16.0 ± 1.8 3.5 ± 2.0 17.3 ± 1.3
B 12.5 ± 1.4 15.1 ± 2.4 3.7 ± 1.8 16.5 ± 2.0
C 13.5 ± 2.5 17.6 ± 2.9 5.1 ± 2.3 19.1 ± 2.6
D 13.0 ± 2.6 17.0 ± 3.0 5.0 ± 1.9 16.7 ± 5.0
E 11.9 ± 4.2 14.5 ± 4.8 3.9 ± 2.5 17.3 ± 3.1
F 12.7 ± 1.4 15.5 ± 1.8 3.8 ± 2.0 17.4 ± 1.9
G 14.1 ± 2.3 17.1 ± 2.5 4.0 ± 2.8 18.7 ± 2.2
Data presented as average ± standard deviation. DMIN was calculated using
DMIN = T1(MIN) − T0(MIN) + 1. DMIN, total time over which each MIN lesion was
detected; MIN, mammary intraepithelial neoplasia; T0(IC), average age when
invasive cancer is first detected; T0(MIN), time when MIN is first detected; T1
(MIN), average age when MIN is last detected.
Figure 5 Determining the transition time from a tumor growth
curve. (a) Plot of the tumor volume (black dots) calculated as a
function of mouse age and fitted (red line) with the simple
exponential tumor growth model. (b) The corresponding plot of r(t)
values as a function of mouse age.
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TT using only two points. In this case, the DT as calcu-
lated here is a more suitable option. Changes in growth
rate at 16 weeks suggest a significant change in the biol-
ogy of the cancers. Since the TT coincides roughly with
the average time at which many in situ cancers become
invasive, this suggests that cancers which successfully es-
cape from the ductal lumens grow much more rapidly
when they become invasive. Some cancers may become
more indolent at 16 weeks because they are nutrient
limited inside the ducts, and are not able to successfully
invade and grow outside the ducts.
Previous studies have suggested that in situ cancer may be
overdiagnosed and overtreated because not all in situ can-
cers will progress to invasive cancer [16-20]. The present re-
sults show a wide range of progression rates, and a wideFigure 4 Specific growth rate for seven different mice. +, mean;
boxes, 25th, 50th, and 75th percentiles; whiskers, 5th and 95th
percentiles; *, upper and lower limits of the data.range of ages at which MIN and invasive cancers were first
detected. A significant number of cancers became more in-
dolent or did not progress during the study period. The fact
that this wide range of growth rates are found in a trans-
genic mouse model that is strongly disposed to develop ag-
gressive cancers is consistent with the view that many
human cancers, especially in situ cancers, may not be dan-
gerous [21].
The results presented here provide a foundation for the
use of the SV40 Tag mouse model (and perhaps other
mouse models) to guide the development of improved
image-based diagnostic and prognostic parameters that
would have important clinical and research applications. In
future studies, we will use functional imaging methods (for
example, dynamic contrast-enhanced MRI and diffusion-
weighted MRI) to identify image-based markers that can re-
liably predict whether cancers will become aggressive or in-
dolent, and could be used in a clinical setting. Such markers
would have an important impact on the clinical manage-
ment of breast cancer and breast cancer risk. In addition,
we will extend the research reported here to obtain more
detailed information about the biology, including the genet-
ics, of aggressive and indolent cancer.
By scanning whole body mouse mammary glands, we
identified many more cancers than in our previous study, in
Figure 6 Doubling time calculated before and after the transition time for 74 lesions. Red line, the line at which the doubling time after
the transition time (TT) = the doubling time before the TT.
Figure 7 Tumor volume measured at week 18 versus the ratio of doubling times before the transition time to after the transition time
(before/after the transition time), for 74 lesions. Lesions are the same as those in Figure 6. DT, doubling time; TT, transition time.
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allowed a more meaningful evaluation of the growth pat-
terns of cancers in these mice. Among the 121 cancers iden-
tified in all seven mice, more than 60% (77) lesions were
identified in the upper glands. In addition, the largest cancer
in each mouse often appeared in upper glands. The reasons
for this difference between upper and lower glands are not
understood, although it may be due to differences in blood
supply to the two areas.
Previous work in this laboratory demonstrated that MIN
lesions and invasive cancers can be identified and distin-
guished by MRI based on the signal intensity, size and
shape [3]. The methods used here built on this previous re-
search to monitor the transition from in situ to invasive
cancer. The criteria used to separate in situ from invasive
cancers are not perfect. However, previous research demon-
strated that T2-weighted images have high diagnostic ac-
curacy; using histology as a gold standard. Therefore, it is
likely in the present study that there were very few missed
or misclassified cancers, and very few false positives.
There are several limitations to this study. First, despite
the high diagnostic accuracy mentioned above, some can-
cers may have been missed due to limited spatial resolution
and signal-to-noise ratio. Second, there are inevitable partial
volume effects that cause errors in measurements of the
tumor volume, especially in the case of smaller in situ can-
cers. Manual delineation of tumor boundaries may have
caused additional errors in tumor volume measurements,
and computer-aided segmentation may increase accuracy in
the future. Finally, mice were scanned every 2 weeks. More
frequent samples may be needed, especially at 14 to 18
weeks, to follow the transition from the slow growth phase
to the more rapid growth phase.
Conclusions
Despite these limitations, the present study provides infor-
mation regarding the growth patterns of in situ and inva-
sive murine mammary cancers that has not previously
been available. This information provides new insights
into the natural history of early murine cancers. Given the
similarity between this murine breast cancer model and
human breast cancer, these insights are probably also rele-
vant to human breast cancer. The data discussed here as
well as future extensions of these experiments can help to
address fundamental questions regarding the natural his-
tory of ductal carcinoma in situ. These questions cannot
be answered by studies of humans. Owing to obligate sur-
gical excision of newly diagnosed cancers, lesion progres-
sion cannot be followed. Serial imaging of mouse models
of breast cancer will therefore be critical for improving
understanding of breast cancer, and developing new diag-
nostic methods and treatments. In particular, we antici-
pate that the results reported here will lead to the
development of functional and anatomic markers thatpredict the transition from in situ to invasive cancer. Such
markers would have applications to both routine clinical
practice and research.
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